Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma

  • STATUS
    Recruiting
  • End date
    Jun 23, 2022
  • participants needed
    295
  • sponsor
    Assistance Publique - Hôpitaux de Paris
Updated on 23 January 2021
ct scan
methotrexate
rituximab
maintenance treatment
bone marrow biopsy
temozolomide
whole-brain radiotherapy
neurotoxicity
primary cerebral lymphoma

Summary

Hypothesis

Our hypothesis is that maintenance chemotherapy will prolong complete remission obtained after a standard induction chemotherapy with an acceptable toxicity in the elderly.

Rationale

  • Treatment of the elderly is challenging, indeed age over 60 is associated both with a poor prognosis and a high risk of treatment induced neurotoxicity with devastating consequences on quality of life. Therefore it has become standard practice to treat elderly in first line with high-dose methotrexate (MTX) based polychemotherapy alone, avoiding whole brain radiotherapy (WBRT) or deferring it for recurrence.
  • There is a clear need to improve disease control after induction chemotherapy. Since consolidation with WBRT or intensive chemotherapy with autologous stem cell rescue are either poorly effective and/or too toxic in the elderly population, maintenance chemotherapy is an interesting alternative approach. Several agents, such as high-dose MTX, temozolomide (TMZ), rituximab, with a reported activity in PCNSL and acceptable safety profile, as single agent or combined, are good candidates for maintenance

Description

Objectives

  • The primary objective is to evaluate the benefit estimated by the PFS associated with maintenance chemotherapy compared to observation in patients 60 years having achieved a complete response after a high-dose MTX based induction chemotherapy
  • The secondary objectives are to assess:
  • Overall survival
  • Safety of maintenance chemotherapy
  • Neurocognitive outcome
  • Quality of life of the patients

Inclusion and exclusion criteria

At registration

  • Inclusion criteria
  • Newly diagnosed primary cerebral lymphoma
  • Age >60 years
  • Pathology proven diagnosis
  • Positive cytology of the CSF or vitreous
  • Karnofsky Performance Status >40
  • No evidence of systemic NHL (body CT scan, bone marrow biopsy)
  • Adequate haematological, renal and hepatic function
  • Calculated creatinine clearance > 40 ml/min
  • Non inclusion criteria
  • Positive HIV serology
  • Preexisting immunodeficiency (organ transplant recipient)
  • Prior treatment for PCNSL
  • Isolated primary intra-ocular lymphoma
  • Low grade lymphoma
  • Any other active primary malignancy

At randomization

  • Complete response on MRI after induction chemotherapy according to the IPCG criteria
  • Karnofsky Performance Status >40
  • Adequate haematological, renal and hepatic function

Study Design

  • This study is an open label multicenter randomized phase III trial comparing maintenance chemotherapy versus observation in complete responders to high dose MTX based induction chemotherapy.
  • Patients are registered to participate in the study at time of initial diagnosis and study enrolment before the induction chemotherapy.
  • Induction chemotherapy (R-MPVA protocol) includes 4 to 5 monthly cycles of high dose MTX (3.5g/m2, D1 and D15), procarbazine, vincristine, rituximab followed by one cycle of high dose cytarabine consolidation.
  • Randomization to observation (arm 1) or maintenance (arm 2) will be carried out only for patients in complete response (CR) after induction chemotherapy Arm 1: Observation Arm 2: Seven monthly R-MT cycles including high dose MTX (3.5g/m2, D1), TMZ, rituximab

Sample size, duration of the study, feasibility

  • 295 patients need to be enrolled to randomize 192 patients
  • Duration of the study: 6 years (accrual period= 4 years; minimal follow-up = 2 years)

26 participating expert centers from the national LOC network

The trial is supported by the neurooncology ANOCEF and the lymphoma LYSA clinical research groups.

Ancillary study LOCALYSE:

Role of [18F]-FDG brain PET in newly diagnosed primary cerebral lymphoma, in immunocompetent patient older than 60 years

Rationale Patients older than 60 years account for half of cases of PCNSL and have a poorer outcome. No prognostic or predictive factors exist for survival after initial remission. [18F]FDG-PET (Fluoro Deoxy Glucose) plays a key role in grading and therapy monitoring of systemic diffuse large B-cell type.

LOCALYZE is an ancillary PET/MR clinical study from BLOCAGE 01. The aim is to evaluate the usefulness of [18F]FDG-PET to monitor treatment response in PCNSL (Primary Central Nervous System Lymphoma) older than 60 years (n=56), in complement to multiparametric MRI.

Hypothesis We assume that the development of new imaging biomarker extracted from PET imaging and multiparametric MRI, could improve the assessment of treatment response in PCNSL.

Primary aim To evaluate the predictive value of [18F]FDG-PET assessment performed at the end-of-treatment (high-dose methotrexate based polychemotherapy), on progression free survival in newly diagnosed PCNSL with age 60 years (n=56).

Primary Outcome Measures:

Progression free survival calculated from the date of completion of the end of chemotherapy PET

Study design

Three [18F]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Piti-Salptrire Hospital:

  • prior to initiation of R-MPVA chemotherapy (Rituximab Methotrexate Procarbazine Vincristine Aracytine ) (PET#1),
  • after two chemotherapy cycles (PET#2),
  • at the end of the first-line chemotherapy regimens (PET#3).

Inclusion criteria (=Blocage-01) Blocage01 eligibility

Exclusion criteria

  • Uncontrolled diabetes with fasting glycaemia > 200 mg/dL
  • Sensitivity to active substance in [18F]-FDG
  • Calculated creatinine clearance < 40 ml/min
  • No contraindication to MRI

Details
Condition Primary Central Nervous System Lymphoma, Central Nervous System Lymphoma, Primary CNS Lymphoma, cns lymphoma
Treatment Rituximab, Methotrexate, Temozolomide
Clinical Study IdentifierNCT02313389
SponsorAssistance Publique - Hôpitaux de Paris
Last Modified on23 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 60 yrs?
Gender: Male or Female
Do you have Primary Central Nervous System Lymphoma?
Do you have any of these conditions: cns lymphoma or Central Nervous System Lymphoma or Primary CNS Lymphoma or Primary Central Nervous System Lymphoma?
newly diagnosed primary cerebral lymphoma
Age 60 years
Pathology proven diagnosis or positive cytology of the CSF or vitreous
Karnofsky Performance Status 40
No evidence of systemic NHL (body CT scan, bone marrow biopsy)
Adequate haematological, renal and hepatic function
Calculated creatinine clearance > 40 ml/min
At randomization
Complete response on MRI after induction chemotherapy according to the IPCG criteria
Karnofsky Performance Status 40
Adequate haematological, renal and hepatic function

Exclusion Criteria

Positive HIV serology
Preexisting immunodeficiency (organ transplant recipient)
Prior treatment for PCNSL
Isolated primary intra-ocular lymphoma
Low grade lymphoma
Any other active primary malignancy
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note